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Abstract
The limb girdle muscular dystrophies are a heterogeneous group of conditions characterized by proximal muscle weakness and disease
onset ranging from infancy to adulthood. We report here eight patients from seven unrelated families affected by a novel and relatively mild
form of autosomal recessive limb girdle muscular dystrophy (LGMD2) with onset in the first decade of life and characterized by severe
mental retardation but normal brain imaging. Immunocytochemical studies revealed a significant selective reduction of a-dystroglycan
expression in the muscle biopsies. Linkage analysis excluded known loci for both limb girdle muscular dystrophy and congenital muscular
dystrophies in the consanguineous families. We consider that this represents a novel form of muscular dystrophy with associated brain
involvement. The biochemical studies suggest that it may belong to the growing number of muscular dystrophies with abnormal expression
of a-dystroglycan.
q 2003 Published by Elsevier B.V.
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1. Introduction
Autosomal recessive limb girdle muscular dystrophy
(LGMD2) is a heterogeneous group of myopathies charac-
terized by progressive muscle weakness involving the
proximal muscles of the shoulder and pelvic girdles and a
variable progression with symptoms ranging from Duch-
enne-like to milder, later onset forms [1,2]. Ten LGMD2
loci and their respective genes have been identified: these
include the enzymatic protein calpain 3 (CAPN3, respon-
sible for LGMD2A, on 15q) [3], the sarcolemmal proteins
dysferlin (LGMD2B, 2p) [4,5], a, b, g and d sarcoglycans
(LGMD2D, 2E, 2C and 2F) [6–10] and LGMD2G mapping
to 17q11–q12, the gene product of which is the sarcomeric
protein telethonin [11]. The genes for LGMD2H, LGMD2I
and LGMD2J have recently been identified: LGMD2H is
due to mutations in the tripartite-motif containing gene 32
(TRIM32), an ubiquitin ligase putatively involved in
proteasome degradation [12] whilst the gene encoding the
giant sarcomeric protein titin is mutated in LGMD2J [13].
The gene responsible for LGMD2I is unusual in that it
encodes a putative glycosyltransferase, the fukutin related
protein gene (FKRP). This gene has been found to be
mutated in patients with phenotypes ranging from severe
congenital muscular dystrophy (MDC1C) to a mild form of
limb girdle muscular dystrophy [14,15]. Abnormal
a-dystroglycan expression is a feature of both MDC1C
and LGMD2I, suggesting that FKRP might be involved in
a-dystroglycan processing.
Dystroglycan is a central component of the dystrophin–
glycoprotein complex (DGC), which links dystrophin to
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the extracellular matrix. In skeletal muscle it consists of a
156 kDa extracellular subunit (a-dystroglycan) and a 43
kDa transmembrane subunit (b-dystroglycan) [16].
a-Dystroglycan is a heavily glycosylated protein
expressed in a wide variety of cell types. In muscle it is a
high-affinity receptor for several extracellular matrix
molecules containing LG domains, including agrin [17],
laminin a chains [18], perlecan [19] and biglycan [20],
whilst in brain it also binds neurexin [21].
The interactions between a-dystroglycan and many of its
extracellular binding partners are mediated by its carbo-
hydrate side chains. a-dystroglycan contains both N-linked
and O-linked carbohydrates. N-Linked glycosylation is less
common but is required for the proper cell surface
localization of both a- and b-dystroglycan [22]. O-Linked
glycosylation is the predominant modification and respon-
sible for the high affinity binding of a-dystroglycan to its
ligands [18].
To date, no disease has been found that is due to primary
mutations in dystroglycan, although a mild form of
muscular dystrophy associated with a secondary b-dystro-
glycan deficiency has been described [23]. In addition to
LGMD2I, abnormal a-dystroglycan expression has been
documented in several forms of congenital muscular
dystrophy (CMD), with and without central nervous system
(CNS) involvement. These include Fukuyama CMD
(FCMD) [24], MDC1C [15], muscle–eye–brain disease
(MEB) [25] and Walker–Warburg syndrome (WWS) [26].
In the present study, we report seven families with
identical clinical features, characterized by relatively mild
and static proximal muscle weakness, mild muscle
hypertrophy, elevated serum creatine kinase (CK), micro-
cephaly and mental retardation but normal brain imaging.
The expression of a-dystroglycan was found to be reduced
in their skeletal muscle biopsies. Linkage analysis
excluded all the mapped forms of muscular dystrophies
in consanguineous families, suggesting these patients
represent a new variant of muscular dystrophy.
2. Patients and methods
2.1. Patients
Over the past decade, we have evaluated a large series of
autosomal recessive LGMD families, the majority of which
have been reported in two consecutive papers which
combine clinical and genetic features [27,28]. Nine of the
families studied did not map to any of the known LGMD
loci and were referred to as ‘unlinked’. Among these, there
were six Turkish families sharing an almost identical
phenotype who form the basis of the present study. More
recently, a British family was seen at the Hammersmith
Hospital (London, UK) with very similar clinical features. A
summary of the clinical features of all families in this study
are given in Table 1. Typically, all patients presented in the
first decade of life with fatigability, difficulty in climbing
stairs and in running. They acquired early motor milestones
at a normal age, excluding a congenital muscular dystrophy.
All were characterized by only mild muscle pseudohyper-
trophy and a slow disease evolution. All had mild to severe
mental retardation, i.e. IQ levels being on average around
50 – 55. Serum CK was invariably grossly elevated
(9–20 fold increase).
For illustrative purposes the case histories of two patients
are presented below.
2.1.1. Case 1
This is a 22-year-old male coming from a first-degree
consanguineous marriage who walked at 3 years. His early
motor milestones were otherwise normal; symptoms started
around 6 years of age with difficulty in gait. His intellectual
Table 1
Clinical characteristics
Current
age/onset
(years)
Sex Consang-
uinity
Family
history
Age
walked
(years)
Maximum
motor
capacity
Hypertrophy Joint
contractures
H.C. % IQ CK CT/MRI Evolution
Case 1 22 (6) M (þ) (þ ) 3 Walks alone Calves Elbow, Achilles 3–10p 50 £ 9 N Mild
Case 2 16 (3) F (þ) (2) 3 Walks alone Calves Achilles 3–10p 55 £ 20 N Mild
Case 3 6 (2.5) F (þ) (2) 3 Walks alone Thigh,
calves
– 10p 65 £ 28 N Mild
Case 4 10 (1) M (þ) (2) 3 Walks alone (2) (2) 3p 50 N Mild
Case 5 9 (3) M (þ) (2) 3 Walks alone (2) (2) 10–25p 50 £ 40 N Mild
Case 6 10 (3) M (2) (2) 3 Walks alone Thigh, calves,
upper arms
(2) 50p 55 £ 25 N Mild
Case 7a 12 (5) M (þ) a 1.5 Walks alone Thigh, calves Achilles 3p 76 £ 22 N Mild
Case 8a 15 (4) F (þ) a 2 Walks alone Thigh, calves,
hamstring,
upper arm
Achilles 3p 57 £ 24 N Mild
H.C., head circumference; CK, creatine kinase; CT/MRI, computed tomography/magnetic resonance imaging; p, centile; N, normal.
a Siblings.
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milestones were, however, clearly delayed; he said his first
few words at 3 years, but later on failed to learn to read and
write. When examined at 11 years of age, Gowers sign was
negative, he raised himself from the floor in less than 3 s and
his proximal muscle strength was MRC 4þ/5. Serum CK at
the time was 2327 U/l (normal , 190Þ. At the age of 16
years, his proximal weakness had increased and he now had
a positive Gowers manoeuvre in 4–5 s. A repeated CK was
1931 U/l. When re-examined at 22 years, his head
circumference was 53 cm (3–10 centile); muscle weakness
had remained virtually static, with muscle power MRC 4/5
proximally. His calves were mildly enlarged. He had
increased lumbar lordosis with mild elbow and ankle
contractures (Fig. 1). Gowers sign was positive with 7–8 s.
He could walk for long distances without significant
difficulties. There was no prominent facial weakness or
scapular winging. With regard to his intellectual function,
he was unable to count money or take a bus ride in the city
alone, and formal testing disclosed an IQ of 55. Out of nine
siblings, his 7-year younger brother is similarly affected.
2.1.2. Case 2
This is a 16-year-old girl coming from a second-degree
cousins marriage with no other relevant family history. The
onset was around 3 years of age, shortly after she started to
walk. Her initial difficulties were an unsteady gait and
difficulties climbing stairs. This later progressed to a
waddling gait with a Gowers manoeuvre of 10 s at the age
of 14 years. At the last visit at the age of 16 her head
circumference was 53 cm (3–10 centile). Currently, she has
mild enlargement of the calves and ankle contractures as
well as increased lumbar lordosis. There is no facial
weakness nor muscle atrophy. Her proximal muscle strength
is MRC 3þ/5. She is independently ambulant, but only for
short distances, 25–30 m. Her intellectual development was
slow: she said her first few words at 7 years and now, aged
16, she only uses two-word sentences. Her IQ is 50. She is
also unable to count money and perform independent
activities. The CK at the age of 15 is 4133 U/l (normal
, 209Þ. Her cranial magnetic resonance image (MRI) is
normal. This case represents the most severely affected
patient in our series.
2.2. Genotyping
Genomic DNA was extracted from whole blood by
standard methods after obtaining informed consent. Highly
polymorphic markers of chromosomes 2p13–p16, 4q12,
5q33–q34, 13q12, 15q15.1–q15.3, 17q12–q21.33 were
analysed for these six LGMD2 families in the previous
study [28]. The markers used in this study were the
following: LGMD2G (D17S1851, D17S1818, D17S1814);
LGMD2H (D9S1811, D9S195, D9S1872, D9S1850);
LGMD2I (MDC1C) (D19S412, D19S606, D19S596,
D19S879). In addition, the following loci responsible for
the following CMD syndromes were excluded: LAMA2
with markers D6S407, D6S1705, and D6S1620 [29–31];
RSMD1 with markers D1S458, D1S2674, D1S234,
D1S2885, and D1S511 [32]; MEB with markers D1S211,
D1S2677, D1S427, D1S2652, and D1S200 [33]; FCMD
with markers D9S2105 and D9S2107 [34]; and MDC1B
(D1S213, D1S2833, D1S2709, D1S459 [14]). In addition,
the FKRP gene was sequenced in all families as already
described [15].
(CA)n microsatellite markers were provided from the
Genethon human genetic linkage map [35]. Haplotypes
were constructed by minimizing the number of recombina-
tion events. Linkage was ascertained by homozygosity by
descent.
2.3. Immunocytochemistry
Unfixed frozen 8-mm sections were incubated with
monoclonal antibodies to b-spectrin, dystrophin, a-, b-,
g-, and d-sarcoglycan, laminin a2, b-dystroglycan (all
available from Novocastra Laboratories), and a-dystrogly-
can (VIA4-1, Upstate Biotechnology) for 1 h. Then, a
biotin-conjugated secondary antibody (Amersham) and
Texas Red-conjugated streptavidin (Amersham) were
applied to all sections for 45 and 30 min, respectively. All
dilutions and washings were made in phosphate buffered
saline. Sections were examined by a Leica Aristoplan
microscope.
2.4. Immunoblotting
Immunoblot analyses were performed in two patients
(cases 1 and 2) as described by Piccolo et al. [36]. The
primary antibodies used were against, respectively, dystro-
phin (DYS1 and DYS2, Novocastra 1:100), a-, b-, g- and
d-sarcoglycan (Novocastra 1:50).Fig. 1. Case 1: can easily raise arms above head, mild pseudohypertrophy, IQ 55.
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2.5. Immunoprecipitation
Co-immunoprecipitation was carried out using a
previously reported protocol by Kessler et al. [37] with
the following modifications. Muscle tissue (0.25 cm3)
was homogenized by Dounce homogenizer in 100 ml
RIPA (1% NP-40,1% sodium deoxycholate, 0.1% SDS,
150 mM NaCl, 100 mM sodium phosphate, pH 7.2)
containing 1£ protease cocktail (Roche Biochemicals)
and centrifuged. The supernatant was retained, and
incubated overnight at 4 8C with 25 ml protein-G-
Sepharose (Pharmacia) coupled with antibodies specific
to anti-a-dystroglycan (polyclonal antibody, courtesy of
Dr Stephan Kro¨ger, 1:100) [38] antibodies. Subsequently,
the beads were washed three times with RIPA, boiled in
Laemmli buffer and applied into 10% sodium dodecyl
sulphate–polyacrylamide gel electrophoresis. They were
then transferred onto nitrocellulose membranes and
blotted with anti-b-dystroglycan antibodies (Novocastra
1:250).
Fig. 2. Immunocytochemical analysis of dystrophin, sarcoglycans (a, b, g, and d), laminin a-2, and dystroglycans (a-dystroglycan (VIA4-1 antibody) and
b-dystroglycan) in cases 1 and 2. Note significantly reduced labelling for only a-dystroglycan.
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3. Results
3.1. Genotyping
All families were haplotyped with microsatellite markers
spanning the loci of autosomal recessive LGMD genes
(LGMD2A, LGMD2B, LGMD2C, LGMD2D, LGMD2E,
LGMD2F, LGMD2G, LGMD2H, LGMD2I) and five CMD
forms (MDC1A, MDC1B, MDC1C, FCMD and MEB). No
family showed haplotypes consistent with linkage to any of
these loci.
3.2. Immunocytochemistry and Immunoblotting
The histological changes on muscle biopsies were
compatible with muscular dystrophy. There was mild
fibrosis with many regenerating and few necrotic fibres.
Variation in fibre size was remarkable; many fibres were
hypertrophic with multiple central nuclei and there were
atrophic fibres most of which were type II. Some angular
fibres were also present.
The expression of all proteins we regularly screen in the
biopsies of patients with muscular dystrophy (dystrophin,
laminin a2, a-, b-, g- and d-sarcoglycans) were normal in
all patients in whom muscle biopsy was available for
immunofluorescence (cases 1, 2, 3, 5, 6, and 7) (Fig. 2:
data shown for cases 1 and 2) and immunoblotting (cases 1
and 2) (Fig. 3). With monoclonal VIA4-1 antibody directed
towards a glycosylated epitope, significantly reduced
labelling for a-dystroglycan was observed in all biopsies
examined (Figs. 2 and 4: data shown for cases 1, 2, and 7).
The muscle biopsies of cases 2 and 7 were also labelled
using the antibody to the core dystroglycan protein and
showed a profound reduction in agreement with that seen
with V1A4-1 (Fig. 4). b-Dystroglycan immunolabelling
was within normal limits in all patients (Fig. 2: data shown
for cases 1 and 2).
3.3. Demonstration of a- and b-dystroglycan complex
We tested the presence of a- and b-dystroglycan
complex formation by co-immunoprecipitation in cases 1
and 2. Co-immunoprecipitation using anti-a-dystroglycan
and immunoblotting using anti-b-dystroglycan demon-
strated that a- and b-dystroglycan were able to form a
complex in both patients (Fig. 5).
4. Discussion
In this study we present a novel and unique LGMD
phenotype. In addition to the classical features of LGMD,
all patients invariably had mental retardation with micro-
cephaly and normal brain imaging. All families but one
were consanguineous. We propose to name this novel
variant recessive limb girdle muscular dystrophy with
Fig. 3. Western blot analysis of dys2, a-, b-, g- and d-sarcoglycans in cases 1 and 2.
Fig. 4. Immunocytochemical analysis of a-dystroglycan by using VIA4-1 and core antibodies in cases 2 and 7.
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mental retardation. From a skeletal muscle point of view,
the course is mild despite onset in the first decade of life in
all cases and different degrees of reduction in a-dystrogly-
can expression. All patients remain ambulant, the eldest
being 22 years old. Standard cranial MRIs failed to show
any evidence of central nervous system malformations or
white matter changes. In addition, none of the patients had
epilepsy, a common complication of neuronal migration
disorders. To our knowledge, such a phenotype has not been
previously described. In addition, with the exception of
LGMD2I, the abnormal expression of a-dystroglycan has
not been reported in other forms of LGMD, further
suggesting that this form represents a new clinical entity.
a-dystroglycan expression was significantly reduced in
skeletal muscle, as judged by using an antibody directed
towards a glycosylated epitope and in two patients using the
antibody to the core a-dystroglycan protein. Similar
findings have been observed in patients with MDC1C, due
to mutations in the FKRP gene (Brown et al., submitted for
publication). However, mutations in the FKRP gene were
excluded in all families. Our experiments also suggest that
the residual a-dystroglycan expression is still capable of
binding to b-dystroglycan. This is important as a-dystro-
glycan associates with Grb2 (growth factor receptor
bound 2), a protein that participates in signal transduction
pathways involving receptor tyrosine kinases [39].
Dystroglycan is a widely expressed and heavily glyco-
sylated protein, but its glycosylation pattern varies in a
tissue-specific and developmental pattern. Recently a new
pathomechanism responsible for several forms of CMD and
for LGMD2I was reported following the identification of
mutations in genes with putative or definite glycosyltrans-
ferase activity [40]. This includes mutations in fukutin and
the fukutin-related-protein gene (FKRP), which are mutated
in FCMD and MDC1C, respectively [14,24,41]. While in
FCMD there are invariably associated structural brain
abnormalities, mutations in the FKRP gene do not usually
affect the brain. Allelic mutations in the FKRP gene were
recently shown also to be responsible for LGMD2I, a very
common form of LGMD in the Caucasian population [15].
Two other CMD forms have recently been demonstrated to
be due to mutations in genes encoding glycosyltransferases,
MEB disease and Walker–Warburg syndrome [25,26].
Both these CMD variants result in CNS defects in the form
of neuronal migration disorders. These findings unequi-
vocally indicate that altered glycosylation is a common
underlying cause of muscular dystrophies. The abnormal
expression of a-dystroglycan suggests that this protein is
abnormally processed in this novel form, and that its
abnormal function might account for both the muscle
weakness and the mental retardation.
Dystroglycan is also expressed abundantly in neurons,
astrocytes, and in the glial-vascular interface, suggesting a
role in maintenance of the blood–brain barrier [42]. This
was further confirmed by the recent finding by Moore et al.
[43] who generated a mouse with a brain-specific deletion of
dystroglycan. This resulted in discontinuities of the pial
surface basal lamina (glia limitans) and brain malformation
including disarray of cerebral cortical layering, fusion of
cerebral hemispheres and cerebellar folia, and aberrant
migration of granule cells. This is similar to the abnorm-
alities demonstrated in the brain of patients with MEB
disease and FCMD. In addition, Michele et al. [21] recently
reported that the abnormal processing of a-dystroglycan in
FCMD and MEB disease abolishes its ability to bind
laminin, agrin, and neurexin. Both agrin and neurexin are
Fig. 5. Co-immunoprecipitation of b-dystroglycan with a-dystroglycan. b-Dystroglycan protein is co-immunoprecipitated with a-dystroglycan by using form
of a-dystroglycan. b-Dystroglycan protein is visualized by immunoblotting using anti-b-dystroglycan antibodies. Healthy individuals’ (HI) skeletal muscle
tissue is used as positive controls (lanes 1, 2, 5, 6). No a-dystroglycan antibody added to negative controls during co-immunoprecipitation (lanes 1, 3, 5, 7).
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neuronal dystroglycan receptors in brain, and it has been
suggested that neurexins’ tightly regulated interaction could
mediate cell adhesion between brain cells [44]. We do not
have sufficient muscle available to study the binding
properties of the a-dystroglycan produced by these patients
to neurexin; we could, however, speculate that this
interaction could be partially affected (and not totally
abolished) in this form of limb girdle muscular dystrophy
with mental retardation.
This form of limb girdle muscular dystrophy is likely to
represent another form of muscular dystrophy secondary to
abnormal glycosylation of a-dystroglycan, adding to the
growing number of muscular dystrophies secondary to
mutations in genes encoding for putative glycosyltrans-
ferases [40].
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